BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Babu KS, Morjaria JB. Emerging therapeutic strategies in COPD. Drug Discov Today 2015;20:371-9. [PMID: 25462534 DOI: 10.1016/j.drudis.2014.11.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Saxena J, Bisen M, Misra A, Srivastava VK, Kaushik S, Siddiqui AJ, Mishra N, Singh A, Jyoti A, Fiorillo L. Targeting COPD with PLGA-Based Nanoparticles: Current Status and Prospects. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/5058121] [Reference Citation Analysis]
2 Zheng D, Wang J, Li G, Sun Y, Deng Q, Li M, Song K, Zhao Z. Preliminary therapeutic and mechanistic evaluation of S-allylmercapto-N-acetylcysteine in the treatment of pulmonary emphysema. Int Immunopharmacol 2021;98:107913. [PMID: 34218218 DOI: 10.1016/j.intimp.2021.107913] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Singla E, Dharwal V, Naura AS. Gallic acid protects against the COPD-linked lung inflammation and emphysema in mice. Inflamm Res 2020;69:423-34. [PMID: 32144443 DOI: 10.1007/s00011-020-01333-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
4 He Y, Liang Y, Han R, Lu WL, Mak JCW, Zheng Y. Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy. J Control Release 2019;314:48-61. [PMID: 31644935 DOI: 10.1016/j.jconrel.2019.10.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
5 Zhang L, Zhang X, Li J, Beck-broichsitter M, Muenster U, Wang X, Zhao J, Mao S. Optimization of budesonide-loaded large-porous microparticles for inhalation using quality by design approach. Journal of Drug Delivery Science and Technology 2019;53:101140. [DOI: 10.1016/j.jddst.2019.101140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Machida K, Kawayama T, Kinoshita M, Ichinose M, Tsuda T, Takata S, Koto H, Yoshida M, Ashihara Y, Kawashima M, Suna H, Inoue H. Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial. Int J Chron Obstruct Pulmon Dis 2019;14:2175-84. [PMID: 31571853 DOI: 10.2147/COPD.S223002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Sonowal H, Saxena A, Ramana KV. Contribution of Aldose Reductase-Mediated Oxidative Stress Signaling in Inflammatory Lung Diseases. Oxidative Stress in Lung Diseases 2019. [DOI: 10.1007/978-981-13-8413-4_12] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Chen J, Tang Y, Liu Y, Dou Y. Nucleic Acid-Based Therapeutics for Pulmonary Diseases. AAPS PharmSciTech 2018;19:3670-80. [PMID: 30338490 DOI: 10.1208/s12249-018-1183-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
9 Sun X, Dong Z, Li N, Feng X, Liu Y, Li A, Zhu X, Li C, Zhao Z. Nucleosides isolated from Ophiocordyceps sinensis inhibit cigarette smoke extract-induced inflammation via the SIRT1-nuclear factor-κB/p65 pathway in RAW264.7 macrophages and in COPD mice. Int J Chron Obstruct Pulmon Dis 2018;13:2821-32. [PMID: 30237706 DOI: 10.2147/COPD.S172579] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
10 Liao Y, Guo Y, Li S, Wang L, Tang Y, Li T, Chen W, Zhong G, Song G. Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters 2018;28:1188-93. [DOI: 10.1016/j.bmcl.2018.02.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
11 Dharwal V, Naura AS. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice. Biochem Pharmacol 2018;150:24-34. [PMID: 29355504 DOI: 10.1016/j.bcp.2018.01.027] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
12 Kaieda A, Takahashi M, Takai T, Goto M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Hamada T, Shirasaki M, Okada K, Snell G, Bragstad K, Sang BC, Uchikawa O, Miwatashi S. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors. Bioorg Med Chem 2018;26:647-60. [PMID: 29291937 DOI: 10.1016/j.bmc.2017.12.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
13 Sethi GS, Dharwal V, Naura AS. Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review. Front Immunol 2017;8:1172. [PMID: 28974953 DOI: 10.3389/fimmu.2017.01172] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
14 Vij N, Min T, Bodas M, Gorde A, Roy I. Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases. Nanomedicine 2016;12:2415-27. [PMID: 27381067 DOI: 10.1016/j.nano.2016.06.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
15 Douthwaite JA, Finch DK, Mustelin T, Wilkinson TC. Development of therapeutic antibodies to G protein-coupled receptors and ion channels: Opportunities, challenges and their therapeutic potential in respiratory diseases. Pharmacol Ther 2017;169:113-23. [PMID: 27153991 DOI: 10.1016/j.pharmthera.2016.04.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]